Suggested remit: To appraise the clinical and cost effectiveness of semaglutide within its marketing authorisation for reducing the risk of major cardiovascular events in people with cardiovascular disease and overweight or obesity
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6441
Provisional Schedule
- Expected publication:
- 14 May 2026
Project Team
- Project lead
- Jennifer Upton
Email enquiries
If you have any queries please email TACommA@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 June 2025 | Invitation to participate |
| 05 June 2025 | Note - Note added to the project documents |
| 27 February 2025 - 27 March 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6441 |
| 27 February 2025 | Note - Note added to the project documents |
| 12 December 2024 | Referral |
| 22 July 2024 - 19 August 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6441 |
| 22 July 2024 | In progress. Scoping commenced. |
| 16 May 2024 | Topic selection |
| 13 May 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual